Virax Research Development from 2010 to 2026

VRAX Stock  USD 0.25  0.02  7.41%   
Virax Biolabs Research Development yearly trend continues to be fairly stable with very little volatility. Research Development is likely to outpace its year average in 2026. During the period from 2010 to 2026, Virax Biolabs Research Development regression line of annual values had r-squared of  0.63 and arithmetic mean of  550,513. View All Fundamentals
 
Research Development  
First Reported
2010-12-31
Previous Quarter
M
Current Value
2.1 M
Quarterly Volatility
778.6 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Virax Biolabs financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Virax Biolabs' main balance sheet or income statement drivers, such as Depreciation And Amortization of 463.5 K, Interest Expense of 31.4 K or Selling General Administrative of 3 M, as well as many indicators such as Price To Sales Ratio of 1.1 K, Dividend Yield of 0.0 or PTB Ratio of 0.59. Virax financial statements analysis is a perfect complement when working with Virax Biolabs Valuation or Volatility modules.
  
Build AI portfolio with Virax Stock
Check out the analysis of Virax Biolabs Correlation against competitors.
The evolution of Research Development for Virax Biolabs Group provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Virax Biolabs compares to historical norms and industry peers.

Latest Virax Biolabs' Research Development Growth Pattern

Below is the plot of the Research Development of Virax Biolabs Group over the last few years. It is Virax Biolabs' Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Virax Biolabs' overall financial position and show how it may be relating to other accounts over time.
Research Development10 Years Trend
Slightly volatile
   Research Development   
       Timeline  

Virax Research Development Regression Statistics

Arithmetic Mean550,513
Geometric Mean219,331
Coefficient Of Variation141.43
Mean Deviation627,717
Median87,000
Standard Deviation778,591
Sample Variance606.2B
Range2.1M
R-Value0.80
Mean Square Error236.6B
R-Squared0.63
Significance0.0001
Slope122,780
Total Sum of Squares9.7T

Virax Research Development History

20262.1 M
2025M
20241.8 M
20231.6 M
2022397.1 K
2021433.7 K
2020120.2 K

About Virax Biolabs Financial Statements

Virax Biolabs investors use historical fundamental indicators, such as Virax Biolabs' Research Development, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Virax Biolabs. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Research DevelopmentM2.1 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Virax Stock Analysis

When running Virax Biolabs' price analysis, check to measure Virax Biolabs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virax Biolabs is operating at the current time. Most of Virax Biolabs' value examination focuses on studying past and present price action to predict the probability of Virax Biolabs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virax Biolabs' price. Additionally, you may evaluate how the addition of Virax Biolabs to your portfolios can decrease your overall portfolio volatility.